Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD28


Brief Information

Name:T-cell-specific surface glycoprotein CD28
Target Synonym:CD28,CD28 Antigen,T-Cell-Specific Surface Glycoprotein CD28,CD28 Antigen (Tp44),Tp44,CD28 Antigens,CD28 Molecule,T-Cell-Specific Surface Glycoprotein
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data


Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 5.29 μM as determined in a SPR assay (Biacore T200) (Routinely tested).


Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) with an affinity constant of 2.72 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name



T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) Phase 1 Clinical City Of Hope National Medical Center Lymphoma, Non-Hodgkin Details
Abatacept (Orban Biotech) Phase 2 Clinical Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases Diabetes Mellitus, Type 1 Details
Lulizumab pegol Lulizumab; BMS-931699 Phase 2 Clinical Bristol-Myers Squibb Company Lupus Vulgaris; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Sjogren-Larsson Syndrome Details
Theralizumab TAB-08; TABO-8 Phase 2 Clinical Theramab Solid tumours; Carcinoma, Merkel Cell; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Psoriasis Details
Reltecimod P2-TA; AB-103 Phase 3 Clinical Atox Bio Peritonitis; Acute Kidney Injury; Fournier Gangrene; Fasciitis, Necrotizing; Soft Tissue Infections Details
B7-2/GM-CSF cancer gene therapy CIT Phase 1 Clinical Radient Neoplasms Details
SAR-443216(Sanofi) SAR-443216 Phase 1 Clinical Sanofi Neoplasms Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Solid tumours Details
ALPN-202 ALPN-202 Phase 1 Clinical Alpine Immune Sciences Solid tumours; Lymphoma Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma Details
Membrane bound ligand T-SIGn virus NG-348 Phase 1 Clinical Psioxus Therapeutics Ltd Neoplasms Details
InHeAb-01 InHeAb-01; bsAB Clinical Neoplasms Details
Acazicolcept ALPN-101 Phase 2 Clinical Alpine Immune Sciences, Abbvie Inc Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation Details
REGN-5668 REGN-5668 Phase 2 Clinical Regeneron Pharmaceuticals Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
REGN-7075 REGN-7075 Phase 2 Clinical Regeneron Pharmaceuticals Solid tumours Details
REGN-5678 REGN-5678 Phase 2 Clinical Regeneron Pharmaceuticals Inc Prostatic Neoplasms Details
FR-104 FR-104; JNJ-3133; VEL-101 Phase 2 Clinical Effimune Arthritis, Rheumatoid; Rejection of organ transplantation; Postoperative Complications Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message